High-Risk Prostate Cancer Patients Benefit From Perioperative Apalutamide Therapy
- On Sunday, May 31, 2026, Johnson & Johnson presented final Phase 3 PROTEUS study results at the American Society of Clinical Oncology meeting in Chicago, showing Erleada plus hormone therapy significantly improved clinical outcomes for high-risk prostate cancer patients.
- Standard care combining surgery and radiation often fails to prevent recurrence; nearly half of high-risk patients see their cancer return, requiring additional treatment and limiting cure potential.
- Patients receiving the combination were nine times more likely to have little to no detectable cancer after surgery, with a 29 percent reduction in recurrence and death risk and six years before requiring subsequent therapy.
- Dana-Farber Cancer Institute researcher Mary-Ellen Taplin called the data "paradigm changing," while J&J medical affairs lead Mark Wildgust said the patient benefit is "unequivocal" and the evidence shows Erleada adds new value.
- Johnson & Johnson plans to work with regulators to secure global approval for the combination therapy, building on more than 340,000 patients worldwide already treated with Erleada in other settings.
16 Articles
16 Articles
Erleada Transforming Prostate Cancer Treatment Paradigm
Johnson & Johnson's drug Erleada, when combined with hormone-blocking therapy, significantly improves outcomes for prostate cancer patients undergoing surgery. A recent study indicates it reduces cancer progression risk and extends time before further treatment is needed. Presented at the ASCO meeting, the findings could change treatment strategies for high-risk patients.
High-risk prostate cancer patients benefit from perioperative apalutamide therapy
High-risk localized and locally advanced prostate cancer patients treated with apalutamide - a next generation neoadjuvant androgen-receptor pathway inhibitor (ARPI) - plus hormone therapy before and after prostate cancer surgery resulted in more major pathologic responses and reduced the risk of metastasis or death, meeting both primary endpoints, in an international phase 3 clinical trial led by principal investigator Mary-Ellen Taplin, MD, me…
Coverage Details
Bias Distribution
- 56% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
